{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:25:49Z","timestamp":1768926349925,"version":"3.49.0"},"reference-count":43,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["6736"],"award-info":[{"award-number":["6736"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2019,2]]},"abstract":"Abstract<\/jats:title>Introduction<\/jats:title>The aim was to evaluate \u201coverall neuropathy\u201d, defined as peripheral paresthesia and Raynaud's phenomenon, in long\u2010term survivors of malignant ovarian germ cell tumors (MOGCT<\/jats:styled-content>s) treated with cisplatin\u2010based chemotherapy (CBCT<\/jats:styled-content>).<\/jats:p><\/jats:sec>Material and methods<\/jats:title>Ninety\u2010three MOGCT<\/jats:styled-content> survivors recorded in Norway in 1980\u20102009 (median follow up: 15\u00a0years) were included in this analysis. Forty\u2010nine received CBCT<\/jats:styled-content> (CBCT<\/jats:styled-content> group) and 44 received other or no chemotherapy (non\u2010CBCT<\/jats:styled-content> group). Applying the scale for chemotherapy\u2010induced neurotoxicity, the prevalence of overall neuropathy (ie score >1 on a 0\u20103 scale) was compared between the two groups. Forty women from the CBCT<\/jats:styled-content> group also underwent neurophysiological and neurological examinations; results from the neurological examination were graded according to the National Cancer Institute\u2010Common Terminology Criteria for Adverse Effects version 4 (NCI<\/jats:styled-content>\u2010CTCAE<\/jats:styled-content> scale v4). These women were then categorized into subgroups of low (\u22643 cycles of CBCT<\/jats:styled-content>, n\u00a0=\u00a023) and high CBCT<\/jats:styled-content> (\u22654 cycles of CBCT<\/jats:styled-content>, n\u00a0=\u00a017).<\/jats:p><\/jats:sec>Results<\/jats:title>Twenty\u2010eight (57%) women from the CBCT<\/jats:styled-content> group reported overall neuropathy, compared with 20 (45%) in the non\u2010CBCT<\/jats:styled-content> group (P<\/jats:italic>\u00a0=\u00a0.06). Of the 40 MOGCT<\/jats:styled-content> survivors in the CBCT<\/jats:styled-content> group who underwent neurophysiological and neurological examinations, 14 (35%) showed NCI<\/jats:styled-content>\u2010CTCAE<\/jats:styled-content> grade \u22651 signs or symptoms of peripheral neuropathy. Pathological findings of NCI<\/jats:styled-content>\u2010CTCAE<\/jats:styled-content> grade 2 or 3 signs or symptoms were found in four survivors (10%) from the high CBCT<\/jats:styled-content> subgroup, all of whom also showed objective signs of neuropathy.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Though about half of our MOGCT<\/jats:styled-content> survivors reported overall neuropathy after CBCT<\/jats:styled-content>, more severe pathological neurological\/neurophysiological findings that impacted daily living were recorded in only 10% of them. Our observations of a similar prevalence of self\u2010reported overall neuropathy in the CBCT<\/jats:styled-content> and non\u2010CBCT<\/jats:styled-content> group, combined with limited objective neurological findings, warrant further study to increase the understanding of the specific pathophysiological pathways of long\u2010term CBCT<\/jats:styled-content>\u2010induced neuropathy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aogs.13477","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T07:25:31Z","timestamp":1538810731000},"page":"240-249","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long\u2010term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin\u2010based chemotherapy for malignant ovarian germ cell tumor"],"prefix":"10.1111","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1936-3453","authenticated-orcid":false,"given":"Olesya","family":"Solheim","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology Oslo University Hospital Norwegian Radium Hospital Oslo Norway"},{"name":"National Resource Center for Late Effects after Cancer Treatment Oslo University Hospital Norwegian Radium Hospital Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Skalleberg","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery Oslo University Hospital Rikshospitalet Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torhild","family":"Warncke","sequence":"additional","affiliation":[{"name":"Department of Neurology Oslo University Hospital Rikshospitalet Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"\u00d8rstavik","sequence":"additional","affiliation":[{"name":"Department of Neurology Oslo University Hospital Rikshospitalet Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Trop\u00e9","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Oslo University Hospital Norwegian Radium Hospital Oslo Norway"},{"name":"Institute of Clinical Medicine Faculty of Medicine University of Oslo Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie D.","family":"Foss\u00e5","sequence":"additional","affiliation":[{"name":"National Resource Center for Late Effects after Cancer Treatment Oslo University Hospital Norwegian Radium Hospital Oslo Norway"},{"name":"Institute of Clinical Medicine Faculty of Medicine University of Oslo Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.4.715"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.701"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-1-22"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000216004.22588.ce"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.08.028"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5189"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq216"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.12.010"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12048"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.02.006"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02341156"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2004.09.013"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S44261"},{"key":"e_1_2_10_16_1","first-page":"883","article-title":"Cisplatin\u2010induced DNA\u2010platination in experimental dorsal root ganglia neuronopathy","volume":"20","author":"Meijer C","year":"1999","journal-title":"Neurotoxicology"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2024"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2006"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.075"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5955(99)00190-2"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.4.574"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4025"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05118-7"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1188\/03.ONF.E48-E54"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.9189"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199903000-00007"},{"key":"e_1_2_10_28_1","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program.NCI guidelines \u2013 expedited adverse event reporting requirements for NCI investigational agents.Bethesda MD:National Cancer Institute 2001."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.10.1457"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.8.1239"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)00006-7"},{"key":"e_1_2_10_33_1","unstructured":"http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-4_QuickReference_5x7.pdf. Accessed June 4 2010."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-5370-6"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199205001-00025"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007853"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.11.2923"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61752-3"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnx231"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2006.11.022"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-1418"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp413"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2006.00718.x"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24981"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faogs.13477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aogs.13477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T12:28:35Z","timestamp":1694694515000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/aogs.13477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,22]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/aogs.13477"],"URL":"https:\/\/doi.org\/10.1111\/aogs.13477","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,22]]},"assertion":[{"value":"2018-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}